Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 56

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 8
Chunk 56
---
 550,000 shares of our common stock, no par value, in block sales to institutional investors, at
an average price of $1.90 per share, through our at-the-market equity offering facility, resulting in net proceeds of $1,003,120.

●
On October 14, 2025, we announced new laboratory findings demonstrating that Telomir-1 kills aggressive pancreatic cancer cells. In laboratory
studies using human pancreatic cancer (PANC-1) cells, Telomir-1 produced a concentration-dependent reduction in cancer cell survival
and mitochondrial activity. These data suggest Telomir-1 influences cellular pathways related to energy metabolism and oxidative balance.
The findings align with previously reported results in triple-negative breast and prostate cancer models, indicating that Telomir-1 may
engage fundamental biological processes involved in cancer cell regulation.

●
On October 17, 2025, we executed a binding Letter of Intent (the “LOI”) to acquire TELI Pharmaceuticals, Inc., a related
party company, securing worldwide rights to its lead investigational therapy, Telomir-1. The transaction aligns Telomir’s U.S.
rights with TELI’s ex-U.S. intellectual property portfolio, which includes filings across Europe, Canada, Mexico, China,
Japan, South Korea, India, Israel, Australia, Argentina, Uruguay, Taiwan, and the United Arab Emirates-creating a single global
owner positioned to capture the full commercial value of Telomir-1 across oncology, metabolic, and age-related diseases. The proposed transaction also includes
up to $5 million in potential contributions, in cash or cash equivalents, from certain TELI shareholders over the duration of the collaboration,
with $1 million due at closing, $2 million upon IND acceptance, and $2 million upon Phase 1/2 initiation. The transaction is subject to
shareholder and board approval.

●
On October 23, 2025, we reported new preclinical data from an in vivo study in mice bearing human aggressive prostate cancer tumors evaluating
DNA-methylation changes in two key defense genes - CASP8 and GSTP1 - following treatment with oral Telomir-1, Rapamycin, chemotherapy,
and combination regimens. Apoptosis (“kill”) and detoxification (“clean”) pathways are two of the body’s
fundamental defense systems against cancer initiation and progression, and Telomir-1’s observed modulation of these pathways through
DNA-methylation